Discovery of Tumor and Treatment Response Biomarkers

肿瘤和治疗反应生物标志物的发现

• 批准号: 10486871
• 负责人: Jennifer Jones
• 金额: $ 13.63万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10486871
• 关键词: Biological Markers; Blood Vessels; CCR; Caring; Cells; Cessation of life; Clinical; Clinical Protocols; Clinical Trials; Development; Disease; Disseminated Malignant Neoplasm; Elements; Goals; Immune; Immune response; Immunosuppression; Immunotherapy; Laboratories; Laboratory Research; Malignant Neoplasms; Mediating; Medical Oncology; Methods; Mission; Modality; Patient Care; Patient Monitoring; Patients; Protocols documentation; Publications; Quality of life; Radiation; Radiation Oncologist; Radiation Oncology; Radiation therapy; Role; Sampling; Stromal Cells; Stromal Neoplasm; Study Section; Surgical Oncology; Translational Research; Tumor Markers; United States National Institutes of Health; Unresectable; Work; clinical practice; cohesion; curative treatments; immune activation; improved outcome; individual patient; irradiation; liquid biopsy; nanobiology; neoplastic cell; patient population; predictive tools; responders and non-responders; response biomarker; response to injury; serine receptor; standard of care; tissue injury; tool; translational research program; treatment response; tumor; tumor progression

As a practicing radiation oncologist, seeking to integrate my laboratory and clinical efforts into a cohesive translational research program, I have focused my clinical practice on the care of patients with metastatic cancers, for whom radiation may be beneficial. These radiation treatments are provided in the setting of their care at NIH, which often includes treatment with some form of immune-directed therapy. This patient population is size-able, and these patients comprised nearly one third of all of the patients treated in the NIH Radiation Oncology Branch across the past two years. To best be able to determine what liquid biopsy or biofluid biomarkers correlate with responses to treatment, the translational research efforts of this project are following a two-pronged approach: 1) collaborating with medical and surgical oncology colleagues at NIH to investigate EVs as biomarkers for tumor status as part of those collaborators' existing protocols, and 2) developing new clinical protocols to capture information and samples from this patient population in a more cohesive and informative manner. Both of these approaches are supported by and provide support to the CCR's clinical translational mission and the basic scientific work ongoing in the Translational Nanobiology Section for the study of EV repertoires. The entirety of this project arises in the context of providing best available care to our patients, whether standard of care or on clinical trial, while seeking to identify better ways to tailor care for individual patients. This effort has led to publication of a number of clinical trials, ongoing progress of several additional clinical trials, and the development of multiple additional new clinical trials that will be submitted for CCR review in the upcoming year.

作为一名执业放射肿瘤学家，我寻求将我的实验室和临床工作整合到一个有凝聚力的转化研究计划中，我将我的临床实践重点放在转移性癌症患者的护理上，对于这些患者来说，放射可能是有益的。这些放射治疗是在 NIH 的护理环境中提供的，其中通常包括某种形式的免疫导向疗法。这个患者群体规模很大，这些患者占过去两年在 NIH 放射肿瘤科接受治疗的所有患者的近三分之一。为了最好地确定哪些液体活检或生物流体生物标志物与治疗反应相关，该项目的转化研究工作采用双管齐下的方法：1）与 NIH 的内科和外科肿瘤学同事合作，研究 EV 作为肿瘤状态的生物标志物，作为这些合作者现有方案的一部分；2）开发新的临床方案，以更具凝聚力的方式从该患者群体中捕获信息和样本 和信息丰富的方式。这两种方法均得到 CCR 的临床转化任务以及转化纳米生物学部分正在进行的 EV 所有研究的基础科学工作的支持，并为其提供支持。整个项目的目的是为我们的患者提供最好的护理，无论是标准护理还是临床试验，同时寻求更好的方法来为个体患者提供量身定制的护理。这项努力导致多项临床试验的发表、多项额外临床试验的持续进展以及多项额外新临床试验的开发，这些试验将在来年提交 CCR 审查。